scholarly journals Epigenetic Silencing of OR and TAS2R Genes Expression in Human Orbitofrontal Cortex At Early Stages of Sporadic Alzheimer’s Disease

Author(s):  
Victoria Cunha Alves ◽  
Joana Figueiro-Silva ◽  
Isidre Ferrer ◽  
Eva Carro

Abstract Modulation of brain olfactory (OR) and taste receptors (TASR) expression was recently reported in neurological diseases. We explored the possible expression and regulation of selected OR and TASR genes in human orbitofrontal cortex of sporadic Alzheimer’s disease (AD) and found that these are expressed and markedly downregulated at early stages. The expression pattern did not follow disease progression suggesting regulation through epigenetic mechanisms. We found an increase of global H3K9me3 levels and substantial enrichment of this repressive signature at ORs and TAS2Rs proximal promoter at early stages, ultimately lost at advanced stages. By mass spectrometry-based proteomic and further validation, we found that H3K9me3 interacts with MeCP2 at early stages and that this protein is increased in sporadic AD. Findings suggest MeCP2 might be implicated in OR and TAS2R genes expression regulation through interaction with H3K9me3, and as an early event, it may uncover a novel etiopathogenetic mechanism of sporadic AD.

2017 ◽  
Vol 7 (4) ◽  
pp. 629-636 ◽  
Author(s):  
Niloofar Bazazzadegan ◽  
Marzieh Dehghan Shasaltaneh ◽  
Kioomars Saliminejad ◽  
Koorosh Kamali ◽  
Mehdi Banan ◽  
...  

2020 ◽  
Vol 11 (10) ◽  
Author(s):  
Xiao-fei He ◽  
Jing-hui Xu ◽  
Ge Li ◽  
Ming-yue Li ◽  
Li-li Li ◽  
...  

Abstract Alzheimer’s disease (AD), the most common form of dementia, is marked by progressive cognitive decline, deposition of misfolded amyloid-β (Aβ) peptide and formation of neurofibrillary tangles. Recently, microglial training has emerged as an important contributor to neurological diseases, which augments the subsequent inflammation. However, how it affects the pathology of AD remains unknown. Here, using a mouse model of sporadic Alzheimer’s disease (SAD) induced by streptozotocin injection, we demonstrated that microglial training exacerbated Aβ accumulation, neuronal loss, and cognitive impairment. In addition, we injected MCC950 to inhibit NLRP3 activation and used an inducible Cre recombinase to delete the NLRP3 gene in microglia. Inhibition or depletion of microglial NLRP3 could protect against the pathologies of SAD and abolish the effects of microglial training. Our results identified microglial training as an important modifier of neuropathology in SAD and demonstrated that activation of NLRP3 inflammasome contributed to the pathologies and microglial training in SAD. Therefore, NLRP3 could be a potential therapeutic target for SAD treatment.


PIERS Online ◽  
2009 ◽  
Vol 5 (4) ◽  
pp. 311-315 ◽  
Author(s):  
Natalia V. Bobkova ◽  
Vadim V. Novikov ◽  
Natalia I. Medvinskaya ◽  
Irina Yu. Aleksandrova ◽  
Eugenii E. Fesenko

Sign in / Sign up

Export Citation Format

Share Document